Abstract
Pancreatic cancer remains one of the most lethal cancers worldwide, with an extremely poor prognosis. This cancer is considered the 5th leading cause of cancer related death. The median survival after diagnosis is generally 2-8 months and five-year survival rate is less than 5%. In recent years, nanotechnology is emerging as a rising approach for drug delivery since it has opened up new landscapes in medicine through introduction of smart nanocarrier systems that can selectively deliver the therapeutic agent in a specific region and in appropriate levels, reducing the adverse side effects. This review covers the main delivery systems developed so far for anticancer drug delivery to the pancreas over a period of 20 years, from polymeric to lipidic-based nanosystems, with a particular emphasis on albumin as core material.
Keywords: Pancreatic cancer, nanoparticles, targeted therapy, polymers, drug delivery, signaling pathways.
Current Drug Metabolism
Title:Pancreatic Cancer Therapy Review: From Classic Therapeutic Agents to Modern Nanotechnologies
Volume: 18 Issue: 4
Author(s): Ana Rebelo, Jesus Molpeceres, Patrícia Rijo and Catarina Pinto Reis
Affiliation:
Keywords: Pancreatic cancer, nanoparticles, targeted therapy, polymers, drug delivery, signaling pathways.
Abstract: Pancreatic cancer remains one of the most lethal cancers worldwide, with an extremely poor prognosis. This cancer is considered the 5th leading cause of cancer related death. The median survival after diagnosis is generally 2-8 months and five-year survival rate is less than 5%. In recent years, nanotechnology is emerging as a rising approach for drug delivery since it has opened up new landscapes in medicine through introduction of smart nanocarrier systems that can selectively deliver the therapeutic agent in a specific region and in appropriate levels, reducing the adverse side effects. This review covers the main delivery systems developed so far for anticancer drug delivery to the pancreas over a period of 20 years, from polymeric to lipidic-based nanosystems, with a particular emphasis on albumin as core material.
Export Options
About this article
Cite this article as:
Rebelo Ana, Molpeceres Jesus, Rijo Patrícia and Reis Pinto Catarina, Pancreatic Cancer Therapy Review: From Classic Therapeutic Agents to Modern Nanotechnologies, Current Drug Metabolism 2017; 18 (4) . https://dx.doi.org/10.2174/1389200218666170201151135
DOI https://dx.doi.org/10.2174/1389200218666170201151135 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Carbonic Anhydrases An Overview
Current Pharmaceutical Design Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design Cellular Actions of Nesfatin-1 on Hypothalamic and Medullary Neurons
Current Pharmaceutical Design NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery
Current Drug Metabolism Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Radioactive Gold Nanoparticle in Two Forms (<sup>198</sup><sub>79</sub>Au GNPs and <sup>99m</sup>Tc-GNPs) for Lung Cancer Antiproliferative Induction and Intralesional Imaging: A Proof of Concept
Anti-Cancer Agents in Medicinal Chemistry Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPARα/γ
Current Signal Transduction Therapy Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Current Diabetes Reviews Old Weapons for New Wars: Bioactive Molecules From Cnidarian Internal Defense Systems
Central Nervous System Agents in Medicinal Chemistry Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design The Dual Role of Free Fatty Acid Signaling in Inflammation and Therapeutics
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design Dipeptidyl-Peptidase IV (DPP IV/CD26)-Activated Prodrugs: A Successful Strategy for Improving Water Solubility and Oral Bioavailability
Current Medicinal Chemistry